Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SELL | P14151 | 2/20 | 0.39 |
| ▸ | SELP | P16109 | 2/20 | 0.39 |
| ▸ | SELE | P16581 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23751427 | 0.88 | SELL (0.47) | EPHX2ALDH1A1SELLSELPSELE | |
| SCHEMBL23751426 | 0.88 | SELL (0.47) | EPHX2ALDH1A1SELLSELPSELE | |
| SCHEMBL15970550 | 0.85 | POLB (0.41) | BTKEPHX2ALDH1A1POLB | |
| SCHEMBL5007222 | 0.85 | POLB (0.41) | BTKEPHX2ALDH1A1POLB | |
| SCHEMBL2370755 | 0.82 | ATM (0.48) | BTKEPHX2ACEAKR1C3AKR1C1 | |
| SCHEMBL18038251 | 0.82 | ATM (0.48) | BTKEPHX2ACEAKR1C3AKR1C1 | |
| SCHEMBL18038167 | 0.82 | ATM (0.48) | BTKEPHX2ACEAKR1C3AKR1C1 | |
| SCHEMBL1543589 | 0.82 | FASN (0.38) | BTKEPHX2ALDH1A1POLB | |
| SCHEMBL2405013 | 0.82 | MME (0.43) | BTKEPHX2GAATSHRPOLB | |
| SCHEMBL23825900 | 0.82 | FASN (0.38) | BTKEPHX2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | ARRIEN PHARMACEUTICALS LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | ARRIEN PHARMACEUTICALS LLC | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053221-B2 | Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activity | MELK, TK1, DCK | BTK 2370/4885EPHX2 3334/4885ACE 3084/4885 |
| US-20200131154-A1 | PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | PAICS, MCL1, TP53 | BTK 1354/4885EPHX2 3802/4885ACE 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.